AC
BMRN icon

Allstate Corporation’s BioMarin Pharmaceuticals BMRN Stock Holding History

Allstate Corporation’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$797K Sell
13,936
-13,590
-49% -$744K 0.01% 843
2026
Q1 		$1.55M Buy
27,526
+17,765
+182% +$1.04M 0.02% 615
2025
Q4 		$580K Buy
9,761
+3,402
+53% +$185K 0.01% 586
2025
Q3 		$344K Buy
+6,359
New +$364K 0.01% 572
2025
Q2 		– Sell
-8,352
Closed -$590K – 222
2025
Q1 		$590K Buy
8,352
+2,758
+49% +$186K 0.02% 473
2024
Q4 		$368K Buy
+5,594
New +$375K 0.01% 551
2023
Q1 		– Sell
-5,978
Closed -$619K – 243
2022
Q4 		$619K Buy
5,978
+155
+3% +$14.6K 0.02% 457
2022
Q3 		$494K Hold
5,823
– – 0.01% 496
2022
Q2 		$483K Sell
5,823
-4,274
-42% -$340K 0.01% 508
2022
Q1 		$778K Buy
+10,097
New +$845K 0.02% 447
2020
Q3 		– Sell
-6,245
Closed -$770K – 669
2020
Q2 		$770K Buy
6,245
+1,982
+46% +$197K 0.03% 317
2020
Q1 		$360K Buy
+4,263
New +$367K 0.01% 441
2019
Q4 		– Sell
-32,536
Closed -$2.19M – 617
2019
Q3 		$2.19M Buy
32,536
+4,727
+17% +$364K 0.04% 275
2019
Q2 		$2.38M Buy
+27,809
New +$2.38M 0.04% 250
2017
Q3 		– Sell
-16,358
Closed -$1.49M – 61
2017
Q2 		$1.49M Sell
16,358
-11,188
-41% -$1.02M 0.08% 129
2017
Q1 		$2.42M Sell
27,546
-11,900
-30% -$1.06M 0.15% 105
2016
Q4 		$3.27M Buy
39,446
+23,121
+142% +$1.99M 0.2% 143
2016
Q3 		$1.51M Buy
+16,325
New +$1.54M 0.11% 131

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Allstate Corporation's BMRN Position: Q2 2026 in Review

Allstate Corporation reduced its BioMarin Pharmaceuticals (BMRN) stake by 49% in Q2 2026, selling an estimated $744K and leaving 13,936 shares worth $797K. The position accounts for 0.01% of the portfolio, ranked #843.

Allstate Corporation first reported a position in BMRN in Q3 2016 and has held it in 18 quarters since. The position peaked at $3.27M in Q4 2016. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Allstate Corporation held 13,936 shares of BioMarin Pharmaceuticals worth $797K as of Q2 2026.
  • Allstate Corporation sold 13,590 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $744K.
  • BioMarin Pharmaceuticals made up 0.01% of Allstate Corporation's portfolio in Q2 2026, its #843 holding.
  • Allstate Corporation first reported a position in BioMarin Pharmaceuticals in Q3 2016 and has held it in 18 quarters since.
  • Allstate Corporation's BioMarin Pharmaceuticals position peaked at $3.27M in Q4 2016.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.